H.C. Wainwright analyst Arthur He downgraded Adaptimmune (ADAP) to Neutral from Buy without a price target after the company agreed to sell Tecelra, lete-cel, afami-cel, and uza-cel cell therapies to US WorldMeds for up to $85M. With only preclinical assets remaining in the pipeline, Adaptimmune has now meaningful near-term catalysts, the analyst tells investors in a research note.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADAP:
- Adaptimmune Sells Cell Therapy Assets to US WorldMeds
- Adaptimmune Settles Litigation with M.D. Anderson Cancer Center
- General Mills upgraded, Trade Desk downgraded: Wall Street’s top analyst calls
- Mizuho downgrades Adaptimmune to Neutral on solvency concerns
- Adaptimmune downgraded to Neutral from Outperform at Mizuho